Adma Biologics (ADMA) Work In Process (2017 - 2026)
Adma Biologics' (ADMA) quarterly Work In Process came in at $57.8 million in Q4 2025, down 6.23% YoY from $61.6 million in Q4 2024, and up 29.93% on a QoQ basis from $44.5 million in Q3 2025.
Adma Biologics (ADMA) Work In Process (2017 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 9 years of Work In Process data on file, last reported at $57.8 million in Q4 2025.
- Quarterly Work In Process fell 6.23% year-over-year to $57.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $57.8 million (down 6.23% YoY) and the FY2025 annual result came in at $57.8 million, down 6.23% from the prior year.
- Work In Process grew to $57.8 million in Q4 2025, from $44.5 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $62.1 million in Q1 2023 to a low of $43.2 million in Q2 2025.
- A 5-year average of $53.1 million and a median of $53.5 million in 2024 frame the typical range for Work In Process.
- Annual changes were most pronounced in 2021 — Work In Process soared 94.66% — and 2025, when it retreated 21.6%.
- Tracing ADMA's Work In Process over 5 years: stood at $59.0 million in 2021, then retreated by 4.74% to $56.2 million in 2022, then slipped by 11.66% to $49.6 million in 2023, then advanced by 24.22% to $61.6 million in 2024, then decreased by 6.23% to $57.8 million in 2025.
- The last three Work In Process figures came in at $57.8 million (Q4 2025), $44.5 million (Q3 2025), and $43.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.44 Mn |
| Dec 31, 2025 | 57.80 Mn |
| Sep 30, 2025 | 44.48 Mn |
| Jun 30, 2025 | 43.17 Mn |
| Mar 31, 2025 | 49.78 Mn |
| Dec 31, 2024 | 61.64 Mn |
| Sep 30, 2024 | 53.48 Mn |
| Jun 30, 2024 | 55.07 Mn |
| Mar 31, 2024 | 49.28 Mn |
| Dec 31, 2023 | 49.62 Mn |
| Sep 30, 2023 | 58.28 Mn |
| Jun 30, 2023 | 59.44 Mn |
| Mar 31, 2023 | 62.09 Mn |
| Dec 31, 2022 | 56.17 Mn |
| Sep 30, 2022 | 47.52 Mn |
| Jun 30, 2022 | 51.14 Mn |
| Mar 31, 2022 | 45.14 Mn |
| Dec 31, 2021 | 58.97 Mn |
| Sep 30, 2021 | 57.26 Mn |
| Jun 30, 2021 | 49.16 Mn |